Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
HIVPRIMEBOOST THERVAC
HIV/AIDS
Framework programme: 5
Project number:
QLK2-CT-2002-01430
EC contribution: € 1 062 554
Duration: 36 months
Type: RS
Starting date: 1 November 2002
Graphic element Improvement of a Therapeutic Adjuvanted Protein HIV Vaccine by Combination with DNA Immunisation in a Prime-Boost Regimen
Keywords: HIV Vaccine; prime-boost; SHIV model; protein vaccine; DNA vaccine; HIV-1/MuLV model

Summary:

The project covers preclinical evaluation of an improvement of an adjuvant protein HIV vaccine that entered clinical evaluation in February 2002.  The improvement will be achieved through a combination of the adjuvanted protein vaccine with particle-mediated immune delivery of DNA (PMID-DNA) in a prime-boost immunisation regimen.  This regimen will be investigated in mice and rhesus monkeys for superior immunogenicity and for efficacy in HAART.

Problem:

The projects work contributes to developing an efficacious HIV-1 vaccine.  The rationale of the immunisation strategy is targeted at preventing disease and eventually showing therapeutic benefit to already diseased individuals.  Both vaccines’ profiles would be of value to public health.

Aim:

The primary aim is to improve an adjuvanted protein clade B HIV vaccine. The secondary aim is to demonstrate, in mice and monkeys, the increase of HIV-specific humoral and cellular immune responses induced by a prime-boost regimen over single modality administration, ie. adjuvanted protein vaccine alone. The efficacy of a prime-boost regimen will be demonstrated in MuLV-mice and SHIV monkey models.

Expected results:

The benefit of a prime-boost approach over a single modality approach demonstrated in preclinical immunogenicity and efficacy studies.  Identification of an optimal immunisation schedule.

Potential applications:

Clinical evaluation of the prime-boost approach combining adjuvanted protein vaccine and PMID-DNA, both in prophylactic and therapeutic setting.

Coordinator:

Gerald Voss
GlaxoSmithKline Biologicals
Rue de l’Institut 89
1330 Rixensart
Belgium
Tel: +32 2 656 8243
Fax: +32 2 656 9009
E-mail: gerald.voss@gskbio.com

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Britta WahrenSwedish Institute for Infectious Disease Control and Microbiology and Tumorbiology Centre
Karolinska Institute
SE-17182 Stockholm
Sweden
Tel: +46 8 457 2300
Fax: +46 8 337 272
E-mail: britta.wharen@smi.ki.se
3Jonathan HeeneyFoundation Biomedical Primate Research Centre (BPRC), Department of Virology
Lange Kleiweg 139
NL-2280 GJ Rijswijk
The Netherlands
Tel: +31 15 284 2660
Fax: +31 15 284 3986
E-mail: heeney@bprc.nl

 
 
top
Graphic element